Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GRK2 | P25098 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.34 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.34 |
| ▸ | PLA2G5 | P39877 | 3/20 | 0.34 |
| ▸ | FAAH | O00519 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 3/20 | 0.33 |
| ▸ | CES1 | P23141 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18941422 | 0.82 | EPHX2 (0.41) | MEN1KMT2ALMNAPOLBGRK2 | |
| SCHEMBL29708102 | 0.80 | EPHX2 (0.44) | LMNAEPHX2MAPK1 | |
| SCHEMBL1133855 | 0.72 | FAAH (0.45) | MEN1KMT2ALMNAPOLBGRK2 | |
| SCHEMBL8768750 | 0.71 | CES2 (0.44) | MEN1KMT2ALMNAPOLBGRK2 | |
| SCHEMBL21518434 | 0.71 | S1PR2 (0.43) | EPHX2 | |
| SCHEMBL21518401 | 0.71 | S1PR2 (0.43) | EPHX2 | |
| SCHEMBL21623897 | 0.71 | S1PR2 (0.43) | EPHX2 | |
| SCHEMBL21623884 | 0.71 | S1PR2 (0.43) | EPHX2 | |
| Hydrochloric Acid SCHEMBL28345403 | 0.70 | CES2 (0.48) | MEN1KMT2ACES2CES1 | |
| SCHEMBL21518394 | 0.69 | TP53 (0.44) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110071100-A1 | SULFOBETAINES FOR CANCER, OBESITY, MACULAR DEGENERATION, NEURODEGENERATIVE DISEASES | TILTAN PHARMA LTD. (IL) | 2011-03-24 | — | — | US | disclosed |
| EP-2285369-A2 | SULFOBETAINES FOR CANCER, OBESITY, MACULAR DEGENERATION, NEURODEGENERATIVE DISEASES | Tiltan Pharma Ltd (IL) | 2011-02-23 | — | — | EP | disclosed |
| WO-2009136396-A2 | SULFOBETAINES FOR THERAPY | TILTAN PHARMA LTD. (IL) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071100-A1 | SULFOBETAINES FOR CANCER, OBESITY, MACULAR DEGENERATION, NEURODEGENERATIVE DISEASES | MSRB3, BHMT2, GPR119 | MEN1 1322/4885KMT2A 1510/4885LMNA 3267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.